Nathan Hutchinson-Jones: Pharmacist-Led Care Optimises Cancer-Associated Thrombosis
Nathan Hutchinson-Jones, Deputy Chair – Trust Thrombosis and Haemostasis Group, shared a post on LinkedIn:
“A great day at the VTE Together conference in Dublin today, where I had the opportunity to talk about:
‘Beyond the prescription: What pharmacists really do in cancer-associated thrombosis (CAT)’
As CAT management has evolved, we now have more anticoagulant options and greater patient choice, but this has also made clinical decision making more complex.
My talk explored how pharmacists can add value beyond prescribing: navigating drug interactions and bleeding risk, supporting procedures, managing complex patients, providing education and safety netting, and helping deliver sustainable models of shared care.
I also shared our experience of developing a dedicated multidisciplinary CAT service at the RUH, where over one in four documented reviews resulted in optimisation of anticoagulant therapy.
None of this happens in isolation. Our service relies on close multidisciplinary working, with our specialist nursing team playing a central role in delivering the clinic, alongside pharmacy support.
For me, the future of CAT care is pharmacist enabled, multidisciplinary and patient centred.
I also think there is an opportunity for nationally endorsed, comprehensive guidance for CAT management, alongside wider adoption of dedicated multidisciplinary CAT clinics as the standard model of care.
Ultimately, it’s about the right anticoagulant, for the right patient, at the right time — with ongoing review throughout the cancer journey.
Thanks to Sarah Garvey and the VTE Together team for the invitation, and to my colleagues at the Royal United Hospitals Bath NHS Foundation Trust — particularly our specialist nursing team, RUH Pharmacy, Sinthiya Punnialingam , Uzo Ibechukwu and Nyasha Manomano — for their support in making this work possible.”
Stay updated with Hemostasis Today.
-
Nov 20, 2026, 17:27Adam Bryant: Great Science, Valuable Connections and a Wonderful Haematology Community at Blood 2026
-
Nov 20, 2026, 17:25Gurpreet Kaurr: Scientific Discussions, New Perspectives and Inspiration at HAEMATOCON 2026
-
Nov 20, 2026, 17:24Bispecific FVIIIa-Mimetic Antibodies in Haemophilia A – CRH French Reference Center for Hemophilia Lyon
-
Nov 20, 2026, 17:23Khalid Rehman: Psychosocial Burden Among Caregivers of Patients with Beta-Thalassemia Major in Pakistan
-
Nov 20, 2026, 17:20Dhinesh Selvaraju: Caplacizumab Becomes the First FDA-Approved Treatment for Pediatric aTTP
-
Nov 20, 2026, 17:19Paris Margaritis: Presenting Preclinical Data on GENV-HEM at the WFH Workshop
-
Nov 20, 2026, 17:18WFH Opens Public Comment on Draft Guidelines for Hemostatic Agents and Prophylaxis
-
Nov 20, 2026, 17:18Ketan Asawale: Consensus on the Management of Cancer-Associated Thrombosis in India
-
Nov 20, 2026, 17:16Ajay Samkaria: The Evolution of Hemostasis Diagnostics with the ACL TOP 70 Series